AstraZeneca Clinical Setbacks Add To Pipeline Woes
Executive Summary
AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline